(NASDAQ:OPTN) OPTINOSE INC. announced positive top line results from Phase 3 clinical study.

June 13, 2022

Shares are up 23% on 1,492 trades today. $2.29 a share on almost 600k volume.

Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients
Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCEs Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients

Conference call and webcast to be held today at 8:30 a.m. Eastern Time

https://finance.yahoo.com/news/optinose-announces-positive-top-line-110000465.html

Pages: 1 2

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.